Alcatel-Lucent SA (ADR) (NYSE:ALU) further underlined leadership in fixed-line ultra-broadband access by reaching the milestone of 5 million VDSL2 vectoring line shipments. The company is also seeing an industry ‘tipping point’ with VDSL2 vectoring shipments now surpassing non-vectored VDSL2 with operators fully embracing the technology as they seek to meet targets for broadband connectivity in their markets. Alcatel Lucent SA (ADR) (NYSE:ALU) net profit margin is -11.50% and weekly performance is -0.78%. On last trading day company shares ended up $3.82. Analysts mean target price for the company is $5.14. Alcatel Lucent SA (ADR) (NYSE:ALU) distance from 50-day simple moving average (SMA50) is -2.56%.
Micron Technology Inc (NYSE:MU) shares traded down 5.6% during trading on Thursday after an insider sold shares in the company, Analyst Ratings.Net reports. The company traded as low as $25.25 and last traded at $25.35, with a volume of 28,870,809 shares trading hands. The stock had previously closed at $26.86. Micron Technology, Inc. (NASDAQ:MU) shares advanced 0.66% in last trading session and ended the day on $26.03. Gross Margin is 29.70% and its return on assets is 15.40%. Micron Technology, Inc. (NASDAQ:MU) quarterly performance is 3.79%.
The Medicines Company (NASDAQ:MDCO) has scheduled a surgery and perioperative care investor and analyst meeting for Thursday, May 22, 2014 from 8:30 am to 12:00 noon. The event will be held at the Company’s Global Center 1 at 8 Sylvan Way in Parsippany, NJ. The meeting is being hosted to highlight The Medicines Company’s second emerging core business of surgery and perioperative care. The Medicines Company (NASDAQ:MDCO) shares moved down -2.63% in last trading session and was closed at $25.52, while trading in range of $25.34 -$26.30. The Medicines Company (NASDAQ:MDCO) year to date (YTD) performance is -33.92%.
Theravance, Inc. (NASDAQ:THRX) announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the Form 10 registration statement filed by Theravance Biopharma, Inc. (“Theravance Biopharma”). As previously announced, the SEC’s declaration of effectiveness is a necessary step for Theravance’s completion of the dividend distribution of Theravance Biopharma’s ordinary shares to the Company’s stockholders of record as of 5:00 p.m. Eastern Time. Theravance Inc (NASDAQ:THRX) ended the last trading day at $27.37. Company weekly volatility is calculated as 5.23% and price to cash ratio as 8.31. Theravance Inc (NASDAQ:THRX) showed a positive weekly performance of 1.90%.
Mylan Inc (NASDAQ:MYL) on Thursday said a court dismissed rival generic drug maker Teva Pharmaceutical Industries Ltd.’s motion to block approval of generic versions of multiple-sclerosis drug Copaxone. Mylan Inc (NASDAQ:MYL) net profit margin is 9.00% and weekly performance is 1.78%. On last trading day company shares ended up $46.96. Analysts mean target price for the company is $60.47. Mylan Inc (NASDAQ:MYL) distance from 50-day simple moving average (SMA50) is -5.85%.